Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-088486
Filing Date
2025-06-20
Accepted
2025-06-20 16:04:06
Documents
1
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 4246
  Complete submission text file 0000950170-25-088486.txt   5917
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Issuer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, 37TH FL NEW YORK NY 10001
Business Address
Miller-Rich Nancy (Reporting) CIK: 0001735084 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39782 | Film No.: 251061274